" class="no-js "lang="en-US"> Poseida Therapeutics Archives - Medtech Alert
Monday, November 11, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board

Poseida Therapeutics, a clinical-stage cell and gene therapy company advancing a new class of treatments […]

Poseida Therapeutics Announces Board Change

Poseida Therapeutics, a clinical-stage cell and gene therapy company advancing a new class of treatments […]

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more